3481. [HLA antigens in rheumatology].3482. [Seronegative spondyloarthritis].3484. [Significance of the antibody-dependent cellular cytotoxicity (ADCC) test].3485. [Benzbromarone in the treatment of gout].3486. [The immunomodulating effect of levamisole in animal experiments].3487. [Changes in the locomotor system in renal disease].3488. [Significance of HL-A antigens in rheumatic diseases].3489. [Effect of adrenal steroids on the function of cells and the proliferation of viruses].3490. [Role of immunological complexes in rheumatoid arthritis].3491. Immune complexes and induced release of lysosomal enzymes from mononuclear phagocytes in the pathogenesis of rheumatoid arthritis.3492. The properdin pathway: mechanisms of complement activation and analogies to the classical pathway.3493. Altered local metabolism of complement components in rheumatoid arthritis.3495. [Incidence and pathomechanism of thrombocytosis in rheumatoid arthritis].3496. [Transfer factor in the treatment of rheumatoid arthritis in children].3497. [Pathomechanism of amyloidosis development in the light of studies on transfer amyloidosis].3498. Critical evaluation of B and T cell markers in man.3499. [Diagnosis and treatment of cervical spondylosis].3500. Immunosuppressive therapy of immunoinflammatory diseases. |